New drug combo aims to fight Hard-to-Treat cancers

NCT ID NCT07298772

Recruiting now Disease control Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new drug called SHR-4375 combined with other anti-cancer treatments in people with advanced solid tumors that no longer respond to standard care. The trial will enroll about 198 participants to check safety, find the best dose, and see if tumors shrink. It is an early-stage study, so results are uncertain but could lead to better options for patients with limited choices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-4375 injection combined with other anti-cancer drugs
What this could lead to: If successful, this could point toward a new combination treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is an early-phase trial with only 198 participants, so the drug may not prove effective or safe enough for wider use. Side effects and limited tumor response are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.